Anew Medical (WENA) said Thursday it secured a US patent covering an RNA splice variant of human Klotho gene "s-KL" for the treatment of cognitive and neurodegenerative diseases.
The patent follows similar patents issued in Europe, China and other Asian markets, according to the company.
The intellectual property portfolio provides the company with rights to develop and commercialize new therapies for neurodegenerative diseases, including Alzheimer's, amyotrophic lateral sclerosis, Parkinson's, and other age-related disorders, the company said.
Price: 0.9505, Change: -0.05, Percent Change: -4.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.